India's drug price management system and its implications have been recommended by the pricing department in the article "2170 China Pharmacy 2007 Vol. 18 No. 28". It suggests implementing necessary pre-policy measures, such as strengthening the management of market drug pricing, conducting market research to verify the authenticity of drug costs, strictly reviewing and approving new drugs, comparing the market prices of similar products, using market prices as parameters, determining the pricing of generic drugs with the same specifications based on content ratios, blocking replacements from the source for drugs and formulations that are artificially overpriced through specification changes, packaging, or being labeled as new drugs. It also emphasizes enhancing supervision over market drug pricing.
The provisions require pharmaceutical companies regulated by the market to submit annual cost schedules. Once inflated pricing is identified, the products will be ordered to adjust to a normal level. If they refuse to comply with government-mandated price cuts, manufacturers will face fines and penalties. In formulating and adjusting drug prices under government pricing procedures, cost investigations and audits must be conducted, referring to actual market buying and selling prices, including focusing on bidding prices. An expert review system for drug pricing should be established, along with an expert verification system and a regional harmonized system for pricing. Government pricing should be published through specified media to enhance public transparency.
On February 25, 2007, the National Development and Reform Commission announced the Code of Practice for Medicine Prices (Interim), clearly stating that developing pharmaceutical prices must involve cost-price surveys, expert evaluations or demonstrations, listening to opinions from all sides, and collective brainstorming to consider programs. I believe that the Code of Practice for Medicine Prices (Provisional) establishes reasonable cost metrics. Experts in pricing should comprehensively assess reducing drug prices, ensuring enterprises maintain a certain profit margin while making them affordable for consumers, thus reasonably satisfying the interests of enterprises, medical institutions, and patients.
In the expert review or verification process, representatives from pharmaceutical trading enterprises, medical institutions, insurance companies, and consumers should be invited to multi-disciplinary discussions to determine drug prices.
Related articles cover topics like Nike Free Run VRF OTDK IGCS, UGG Bottes Pas Cher, IRQ IRPU IODJ North Face Online Shop PMU YRLN PYEA.